Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24315738 | 0.93 | CRBN (0.42) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24315921 | 0.90 | CRBN (0.47) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL26662766 | 0.87 | ALDH1A1 (0.36) | CRBNDDB1ALDH1A1 | |
| SCHEMBL24315924 | 0.87 | CRBN (0.40) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24315758 | 0.87 | CRBN (0.45) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL26666247 | 0.86 | CRBN (0.38) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL24315956 | 0.85 | CRBN (0.43) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL26661851 | 0.85 | CRBN (0.41) | CRBNDDB1ALDH1A1CHRM2OPRM1 | |
| SCHEMBL27013022 | 0.85 | CREBBP (0.37) | CRBNDDB1ALDH1A1BRD4 | |
| SCHEMBL24315925 | 0.84 | CRBN (0.44) | CRBNDDB1ALDH1A1CHRM2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CRBN 50/4885DDB1 215/4885ALDH1A1 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.